Identity and synonyms
This is a drug class, not a molecule; do not normalize to sermorelin.
Nonpeptide agent · Identity or class unresolved
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
Commercial identity or variant awaiting clarification.
Mechanism
SERM is a selective estrogen-receptor-modulator drug class, not one drug’s name.
Evidence and critical reading
Reported scientific and empirical uses
Identity awaiting clarification
May be an ambiguous catalog abbreviation; do not automatically convert it to sermorelin or a specific substance.
Human evidence
Tamoxifen, raloxifene and others have different indications/risks. Class evidence does not identify this product or a regimen.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Tamoxifen, raloxifene and others have different indications/risks. Class evidence does not identify this product or a regimen.
Tamoxifen, raloxifene and others have different indications/risks. Class evidence does not identify this product or a regimen.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Thrombosis, endometrial effects and interactions vary by drug. Resolve the full name before attributing contraindications.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
selective estrogen receptor modulator · 48 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06218303 · Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07862725 · Comparative Efficacy of Antioxidants Alone Versus Combined Therapy With SERMs or FSH in Normogonadotropic Idiopathic OAT Patients: A Randomized Controlled TrialRegistry status: Not yet recruitingLast update posted: October 7, 2026Query verification: October 16, 2026
NCT06075953 · DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRegistry status: RecruitingLast update posted: September 28, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- SEARCH-PUBMED-serm-unspecified
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026